ERBB2 and breast carcinoma: In the adjuvant setting, denosumab was reported to prevent treatment-induced bone loss, to reduce bone metastases, and to improve breast cancer survival in hormone receptor-positive/HER2-negative breast cancer.18, 19, 20 Furthermore, adjuvant denosumab showed a 20%-25% improvement in secondary outcome-related endpoints, with a 3.5 percentage point benefit for DFS at 9 years of follow-up in the ABCSG-18 study.21